The protein expression of RAD52, RAD50, PBX2, MAP2K2 (MEK2), and S100P was also validated with immunohistochemistry in invasive breast cancer tumor tissues (Figure S6 in Supplementary File S1). Here, MAP2K2 is linked to breast carcinoma.